LearnGlossaryMarketStocksSuperinvestorsSign in

PRAX

Praxis Precision Medicines, Inc.

Healthcare · $8.0B market cap

Verdict

We can't put a fair value on PRAX right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-9.6% a year✗
Sales growth249.5% a year✓
Free cash flow growth—?
Return on invested capital-49.2%✗

Follow PRAX

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds PRAX. In Q2 2026, 1 trimmed. Who we track

Polen Capital Management

Polen Capital Management · as of Q2 2026

$2.4M

7,252 shares

Moves in Q2 2026

Trimmed: Polen Capital Management

About Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works